Cynthia Smith Acquires Shares of Agios Pharmaceuticals

Cynthia Smith purchased 2,816 shares of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) on June 18, 2026. This insider transaction wasn't part of a pre-planned trading program and reflects her direct acquisition of shares.

Other Institutional Activity in Agios Pharmaceuticals

Several institutional investors have been active in Agios Pharmaceuticals recently. BlackRock, Inc. increased its holdings by 519,528 shares, bringing its total to 5,754,957 shares valued at approximately $194.7 million, a 9.9% rise. Farallon Capital Management LLC also added 524,495 shares, totaling 5,684,000 shares worth about $192.3 million, marking a 10.2% increase. State Street Corp increased its position by 256,734 shares, ending with 3,364,879 shares valued at $113.7 million, up 8.3%. Conversely, Armistice Capital, LLC reduced its stake by 320,000 shares to 2,716,000 shares, valued at $91.9 million, a decrease of 10.5%. Meanwhile, D. E. Shaw & Co., Inc. significantly boosted its holdings by 843,983 shares, resulting in 2,681,169 shares valued at $90.7 million, a 45.9% increase.

Agios Pharmaceuticals, Inc. Stock Up 3.8%

Shares of Agios Pharmaceuticals traded near $35.47 on Wednesday. The company has a market cap of approximately $2.09 billion. Despite not being profitable, with a forward P/E ratio of -7.44, Agios has been active in the biotechnology sector. The stock's 52-week range is between $22.24 and $46.00, with a 50-day moving average of $29.03 and a 200-day moving average of $31.74. The company maintains a strong liquidity position, with a current ratio of 14.19 and a quick ratio of 12.80.

Recent Earnings

Agios Pharmaceuticals reported revenue of $66.05 million, with a slight growth of 1.38%. The company is not currently profitable, posting an EPS of -$7.27 and a net margin of zero. The return on equity stands at -32.8%. The next earnings report is scheduled for July 30, 2026.

Analysts Set New Price Targets

On June 11, 2026, JP Morgan maintained its hold rating on Agios Pharmaceuticals, setting a price target of $31.00. B of A Securities, on May 29, 2026, maintained a buy rating with a $40.00 target. Truist Securities also maintained a buy rating with a target of $36.00 as of April 30, 2026. The consensus among analysts is a buy recommendation, with a mean price target of $40.75 based on eight analyst opinions.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. The company focuses on discovering and developing medicines in the field of cellular metabolism. Its lead product, PYRUKYND, is used for the treatment of hemolytic anemias in adults with pyruvate kinase deficiency and is in phase 3 trials for sickle cell disease. Agios is also working on treatments for other conditions like myelodysplastic syndrome and phenylketonuria.

Bottom Line

Cynthia Smith's recent purchase of Agios Pharmaceuticals shares highlights insider confidence in the company. The stock trades within a broad 52-week range, and analysts maintain a positive outlook with a buy consensus. Investors often track insider transactions like this as a potential indicator of company prospects.